Latest Hedgehog signaling pathway Stories
The master gene Math1 is involved in the genesis of the most common childhood brain tumor, medulloblastoma, said researchers from Baylor College of Medicine (www.bcm.edu) in a report in the current issue of the journal Science.
Howard Hughes Medical Institute (HHMI) researchers have identified a new factor that is necessary for the development of many forms of medulloblastoma, the most common type of malignant childhood brain cancer.
Researchers at the University of Wisconsin-Madison School of Medicine and Public Health have identified a molecular mechanism that allows two powerful signaling pathways to interact and begin a process leading to colorectal tumors.
Researchers at the California Institute of Technology (Caltech) have proposed a novel model that differs from a widely held hypothesis about the mechanisms by which developing animals pattern their tissues and structures.
Analyses of clinical trial results published today in the New England Journal of Medicine (NEJM) shows a potential new investigational therapy for advanced and metastatic basal cell skin cancer.
The Hedgehog signaling pathway is involved in a preliminary study and case report describing positive responses to an experimental anticancer drug in a majority of people with advanced or metastatic basal cell skin cancers. One patient with the most common type of pediatric brain cancer, medulloblastoma, also showed tumor shrinkage.
Hedgehog trial results suggest antitumor activity in basal cell skin cancer SCOTTSDALE, Ariz., Sept.
Scientists in Switzerland have discovered a way to block the growth of human colon cancer cells, preventing the disease from reaching advanced stages and developing liver metastases.
Elevated levels of GLI1 (glioma-associated oncogene homolog 1) protein in human breast cancer are associated with unfavorable prognosis and progressive stages of disease. Researchers writing in the open access journal BMC Cancer found increased expression of GLI1 in samples taken from more advanced and less survivable tumors.
CAMBRIDGE, Massachusetts and LAUSANNE, Switzerland, August 6 /PRNewswire/ -- Curis, Inc.
- A trick or prank.